Co-trimoxazole prophylaxis in HIV : the evidence

SUNScholar Research Repository

Show simple item record

dc.contributor.author Oliphant, C. E. M.
dc.contributor.author Young, T.
dc.contributor.author Araoyinbo, I.
dc.contributor.author Volmink, J.
dc.date.accessioned 2010-12-22T11:22:45Z
dc.date.available 2010-12-22T11:22:45Z
dc.date.issued 2008-04
dc.identifier.citation Young, T, Oliphant, CEM, Araoyinbo, I & Volmink, J 2008, 'Co-trimoxazole prophylaxis in HIV: The evidence', South African Medical Journal, vol. 98, no. 4, pp. 258-259. en_ZA
dc.identifier.issn 2078-5135 (online)
dc.identifier.issn 0256-9574 (print)
dc.identifier.uri http://hdl.handle.net/10019.1/5501
dc.description Bibliography
dc.description.abstract Human immunodeficiency virus (HIV) damages the body’s immune system, making secondary (or opportunistic) infections more common. Treatment and prevention of such infections is integral to the management of patients with HIV infection. Co-trimoxazole is a prophylactic treatment that has a wide range of action against common bacteria, parasites, fungi and yeasts. As part of a minimum care package, UNAIDS/ WHO recommends co-trimoxazole prophylaxis for HIVinfected adults with symptomatic disease (WHO stage II, III or IV), or asymptomatic individuals with CD4 counts ≤500 cells/μl, and for all HIV-positive pregnant women after the first trimester.1 Co-trimoxazole is also recommended for use in children with proven HIV infection and infants exposed to HIV (from 4 - 6 weeks of age until infection with HIV is ruled out).2 The object of this report is to summarise the effects of co-trimoxazole prophylaxis on morbidity and mortality among HIV-infected individuals. en_ZA
dc.format.extent 2 p.
dc.language.iso en_US en_ZA
dc.publisher Health and Medical Publishing Group (HMPG) en_ZA
dc.subject EMTREE drug terms: antiretrovirus agent; cotrimoxazole; fansidar; placebo EMTREE medical terms: article; bacterial infection; clinical trial; drug dose comparison; drug dose escalation; drug efficacy; drug hypersensitivity; drug tolerability; drug withdrawal; hospital admission; human; Human immunodeficiency virus infection; morbidity; mortality; mycosis; parasitosis; Pneumocystis carinii; Pneumocystis pneumonia; unspecified side effect MeSH: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Humans; Trimethoprim-Sulfamethoxazole Combination Medline is the source for the MeSH terms of this document. en_ZA
dc.subject HIV positive children -- Treatment en_ZA
dc.subject HIV positive children -- Diagnosis en_ZA
dc.subject Antiretroviral therapy in children en_ZA
dc.subject Co-trimoxazole prophylaxis -- Effectiveness en_ZA
dc.subject.lcsh Highly active antiretroviral therapy en_ZA
dc.title Co-trimoxazole prophylaxis in HIV : the evidence en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record